Why involvement of patients is essential for Health Technology Assessment
Patient expertise is equally relevant to decision makingread more …
admedicum joins HollandBIO
The Netherlands is home to a vibrant, dense biotechnology cluster of nearly 1800 life sciences companies and research organizations.read more …
Business for Patients is in our DNA.
Why cooperate with patients?
Including patient expertise during the entire product life-cycle is key for truly patient-focused innovative products and services. It is instrumental for successful business. However, how can this be translated into practice? That’s exactly where admedicum comes in.
We help prepare your organization and shape the patient interactions in a way that creates sustainable value for both patients and your business. We provide “fit for purpose” approaches to establishing concepts, tools, advisory groups, networking, coaching and management support where it can help overcome the challenges of a complex relationship between patients and industry.
We provide down-to-earth day-to-day patient-centric business solutions. Together with our clients from the industry, we make patient-industry collaboration happen. We act as advisors, designers and enablers to build trustworthy and effective relationships between patients and industry. We help to merge beneficial impact for patients and value-for-money for industry.
By systematically involving 390 myotonia patients across 18 European countries through the project MYOPATH, admedicum® was instrumental in demonstrating EMA the great need for patient access to Namuscla® (mexiletine). The EMA Committee of Orphan Medicinal Products (COMP) explicitly highlighted the quality of the MYOPATH survey methodology that led to the capture of important information regarding a lack of treatment access resulting in patient harm.
Ana Mingorance, Chief Development Officer LouLou Foundation, London, UK
The CDKL5 Research & Family conference, which Philipp was instrumental with in shaping the agenda, was an exceptionally great meeting! I had a chance to talk to many of the families and I know they appreciated these days and loved how much opportunity they had to participate and tell their stories and help shape the field and advance it. This was truly the first patient-centric meeting I’ve ever attended, and that was very much thanks to Philipp‘s vision.
Undisclosed pharma participant on the same conference: „You and Carol-Anne organized the best disease-focused family meeting I ever attended. The interaction and co-collaboration amongst all constituents was extremely beneficial to everyone in attendance. I especially appreciated hearing directly from the caregivers their needs and wants for clinical trials and new medications.“
Steffen Stürzebecher, SVP Head of Innovation Unit Specialty Therapeutics, Grünenthal
His vision of a patient centric approach to pharmaceutical development, in particular in rare and orphan diseases, together with the implementation of a concrete series of patient focused events has created a momentum that our company is still benefitting from.
Horst Mehl, past-president and currently honorary president of Mukoviszidose e.V., the German Cystic Fibrosis Association
During his time as CEO of Mukoviszidose e.V., the German Cystic Fibrosis (CF) Association (2002 – 2014) and Managing Director of our research affiliate, Mukoviszidose Institut GmbH (2006 – 2015), I got to appreciate Andreas Reimann. I am a father of a son living with CF and I am grateful to what Andreas has contributed to the lives of ...
Susan Stephenson , RN BSN CCRN Independent Rare Disease Pain Advocate and Consultant N. Chesterfield, VA USA
Philipp possesses all the many skills needed and essential for bringing together patient organizations and their KOLs into the limelight of industry! For more than 30 years, I have promoted genetic diseases and pain awareness as a health professional with a genetic disease and chronic pain.
Dr Jenny Royle, Senior patient-centricity programme leader of Cancer Research UK, on panel facilitator Rachel Jone
Rachel interacts with patients and their families with both tact and ease, ensuring that we end up with networks of people engaged and wanting to be involved. She has an ability that I think is rare to find: naturally picking up on peoples non-verbal as well as verbal meanings very quickly.
Siobhan Southam, Global Communications Lead AstraZeneca
She is differentiated by her skill at delivery and bringing people together to ensure projects always deliver to time and with much good humour along the way! A true people person, she thrives in organisational situations that others might find tricky, embracing change and challenge herself and ensuring that others benefit and grow ...
After an already successful partnership on the Patient Engagement Guide, admedicum has officially joined HollandBIO, an interest group of biotech companies in the Netherlands. admedicum and HollandBIO share the idea that a society in which biotechnology makes a maximum contribution to health, sustainability and economic growth should involve patients. We are happy to become members and benefit from the strong network of HollandBIO and the quality of their meetings and conferences.
The healthcare system of the future sees the patient at the center of events. It talks to patients and not about patients, involving them in a meaningful way when developing new treatments. Communication is open and transparent, and there is joint decision-making with all stakeholders. In tomorrow’s healthcare system, trust and mutual respect are key elements, while any conflicting interests that may arise are honestly declared.
admedicum recently attended the HTAi 2019 meeting in Cologne, Germany entitled, “HTA beyond 2020: Ready for the New Decade?” At admedicum, we believe patient involvement in HTA is crucial for making the right decisions because health technology is FOR THE PATIENTS. We took the opportunity of other stakeholders being in Cologne to co-host a PEGASUS NetworkingEvent to discuss the same topic as this blog with a group of diverse stakeholders including patient-representatives from several different disease-areas.